[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 685292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1063565, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 54000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 59, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 47, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 40, "title": "SVP & Corporate Controller", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.69, "open": 1.72, "dayLow": 1.6905, "dayHigh": 1.78, "regularMarketPreviousClose": 1.69, "regularMarketOpen": 1.72, "regularMarketDayLow": 1.6905, "regularMarketDayHigh": 1.78, "payoutRatio": 0.0, "beta": 0.987, "forwardPE": -1.2230216, "volume": 1914537, "regularMarketVolume": 1914537, "averageVolume": 5343816, "averageVolume10days": 2271110, "averageDailyVolume10Day": 2271110, "bid": 1.67, "ask": 1.71, "bidSize": 18, "askSize": 4, "marketCap": 371798496, "fiftyTwoWeekLow": 1.23, "fiftyTwoWeekHigh": 3.78, "priceToSalesTrailing12Months": 16899.932, "fiftyDayAverage": 1.6852, "twoHundredDayAverage": 2.24175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 167630048, "profitMargins": 0.0, "floatShares": 156350223, "sharesOutstanding": 218704992, "sharesShort": 32811049, "sharesShortPriorMonth": 38012142, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.15100001, "heldPercentInsiders": 0.17545, "heldPercentInstitutions": 0.77219003, "shortRatio": 9.72, "shortPercentOfFloat": 0.2094, "impliedSharesOutstanding": 218704992, "bookValue": 1.989, "priceToBook": 0.8547009, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -257590000, "trailingEps": -1.32, "forwardEps": -1.39, "enterpriseToRevenue": 7619.548, "enterpriseToEbitda": -0.687, "52WeekChange": -0.43521595, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 1.7, "targetHighPrice": 14.0, "targetLowPrice": 3.0, "targetMeanPrice": 9.18182, "targetMedianPrice": 9.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 292476000, "totalCashPerShare": 1.346, "ebitda": -243843008, "totalDebt": 90756000, "quickRatio": 8.287, "currentRatio": 8.541, "totalRevenue": 22000, "debtToEquity": 21.497, "revenuePerShare": 0.0, "returnOnAssets": -0.27011, "returnOnEquity": -0.55134, "grossProfits": -192276992, "freeCashflow": -99133376, "operatingCashflow": -200300000, "revenueGrowth": -1.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -11703.728, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1746230232, "regularMarketTime": 1746216001, "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539264600000, "fiftyTwoWeekHighChangePercent": -0.55026454, "fiftyTwoWeekChangePercent": -43.521595, "earningsTimestamp": 1741896120, "earningsTimestampStart": 1747047540, "earningsTimestampEnd": 1747396800, "earningsCallTimestampStart": 1741899600, "earningsCallTimestampEnd": 1741899600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.32, "epsForward": -1.39, "epsCurrentYear": -1.19976, "priceEpsCurrentYear": -1.4169501, "fiftyDayAverageChange": 0.014800072, "fiftyDayAverageChangePercent": 0.008782383, "twoHundredDayAverageChange": -0.54174995, "twoHundredDayAverageChangePercent": -0.24166386, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "postMarketChangePercent": 0.588235, "postMarketPrice": 1.71, "postMarketChange": 0.00999999, "regularMarketChange": 0.00999999, "regularMarketDayRange": "1.6905 - 1.78", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 5343816, "fiftyTwoWeekLowChange": 0.47000003, "fiftyTwoWeekLowChangePercent": 0.38211384, "fiftyTwoWeekRange": "1.23 - 3.78", "fiftyTwoWeekHighChange": -2.08, "regularMarketChangePercent": 0.5917154, "regularMarketPrice": 1.7, "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]